{"transactions":[{"id":801653,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:39:05.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":118125,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":118125},"source":{"system":"sec-edgar","filing":"0001655962-26-000005","document":"form4-04232026_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000005/form4-04232026_080401.xml","form_type":"4"}},{"id":801652,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:39:05.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":72875,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":72875},"source":{"system":"sec-edgar","filing":"0001655962-26-000005","document":"form4-04232026_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000005/form4-04232026_080401.xml","form_type":"4"}},{"id":801651,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:39:05.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":46375,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":46375},"source":{"system":"sec-edgar","filing":"0001655962-26-000005","document":"form4-04232026_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000005/form4-04232026_080401.xml","form_type":"4"}},{"id":801650,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:39:05.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6750},"source":{"system":"sec-edgar","filing":"0001655962-26-000005","document":"form4-04232026_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000005/form4-04232026_080401.xml","form_type":"4"}},{"id":801649,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:39:05.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":188000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.16,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":188000},"source":{"system":"sec-edgar","filing":"0001655962-26-000005","document":"form4-04232026_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000005/form4-04232026_080401.xml","form_type":"4"}},{"id":801648,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:39:05.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":162000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":162000},"source":{"system":"sec-edgar","filing":"0001655962-26-000005","document":"form4-04232026_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000005/form4-04232026_080401.xml","form_type":"4"}},{"id":801647,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:39:05.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":162000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2034-01-04","underlying":"Common Stock","underlying_shares":162000},"source":{"system":"sec-edgar","filing":"0001655962-26-000005","document":"form4-04232026_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000005/form4-04232026_080401.xml","form_type":"4"}},{"id":801646,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:39:05.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":116000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":116000},"source":{"system":"sec-edgar","filing":"0001655962-26-000005","document":"form4-04232026_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000005/form4-04232026_080401.xml","form_type":"4"}},{"id":801645,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:39:05.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":151000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":151000},"source":{"system":"sec-edgar","filing":"0001655962-26-000005","document":"form4-04232026_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000005/form4-04232026_080401.xml","form_type":"4"}},{"id":801644,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:39:05.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":497667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":497667},"source":{"system":"sec-edgar","filing":"0001655962-26-000005","document":"form4-04232026_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000005/form4-04232026_080401.xml","form_type":"4"}},{"id":801643,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2026-04-23T20:39:05.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":312025,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001655962-26-000005","document":"form4-04232026_080401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000005/form4-04232026_080401.xml","form_type":"4"}},{"id":895688,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-02-18T22:16:10.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":false,"shares":7875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":118125,"derivative":{"underlying":"Common Stock","underlying_shares":7875},"source":{"system":"sec-edgar","filing":"0001655962-26-000004","document":"form4-02182026_100206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000004/form4-02182026_100206.xml","form_type":"4"}},{"id":895687,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-02-18T22:16:10.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":72875,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001655962-26-000004","document":"form4-02182026_100206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000004/form4-02182026_100206.xml","form_type":"4"}},{"id":895686,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-02-18T22:16:10.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":46375,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001655962-26-000004","document":"form4-02182026_100206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000004/form4-02182026_100206.xml","form_type":"4"}},{"id":895685,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-02-18T22:16:10.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":6750,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001655962-26-000004","document":"form4-02182026_100206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000004/form4-02182026_100206.xml","form_type":"4"}},{"id":895684,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2026-02-18T22:16:10.000Z","date":"2026-02-17","kind":"sale","planned":false,"acquired":false,"shares":6065,"price":11.6009,"value":70359.4585,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.195 to $11.8508, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":312025,"source":{"system":"sec-edgar","filing":"0001655962-26-000004","document":"form4-02182026_100206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000004/form4-02182026_100206.xml","form_type":"4"}},{"id":895683,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2026-02-18T22:16:10.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":true,"shares":7875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":318090,"source":{"system":"sec-edgar","filing":"0001655962-26-000004","document":"form4-02182026_100206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000004/form4-02182026_100206.xml","form_type":"4"}},{"id":895682,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2026-02-18T22:16:10.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":310215,"source":{"system":"sec-edgar","filing":"0001655962-26-000004","document":"form4-02182026_100206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000004/form4-02182026_100206.xml","form_type":"4"}},{"id":895681,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2026-02-18T22:16:10.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":303590,"source":{"system":"sec-edgar","filing":"0001655962-26-000004","document":"form4-02182026_100206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000004/form4-02182026_100206.xml","form_type":"4"}},{"id":895680,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2026-02-18T22:16:10.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":296965,"source":{"system":"sec-edgar","filing":"0001655962-26-000004","document":"form4-02182026_100206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000004/form4-02182026_100206.xml","form_type":"4"}},{"id":926753,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Units","published_at":"2026-01-30T22:19:54.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":126000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":126000,"derivative":{"underlying":"Common Stock","underlying_shares":126000},"source":{"system":"sec-edgar","filing":"0001655962-26-000002","document":"form4-01302026_100151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000002/form4-01302026_100151.xml","form_type":"4"}},{"id":926752,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-01-30T22:19:54.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":188000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":188000,"derivative":{"exercise_price":11.16,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":188000},"source":{"system":"sec-edgar","filing":"0001655962-26-000002","document":"form4-01302026_100151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596226000002/form4-01302026_100151.xml","form_type":"4"}},{"id":995106,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-11-19T00:02:25.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":79500,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001655962-25-000006","document":"form4-11192025_121121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000006/form4-11192025_121121.xml","form_type":"4"}},{"id":995105,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-11-19T00:02:25.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":53000,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001655962-25-000006","document":"form4-11192025_121121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000006/form4-11192025_121121.xml","form_type":"4"}},{"id":995104,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-11-19T00:02:25.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001655962-25-000006","document":"form4-11192025_121121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000006/form4-11192025_121121.xml","form_type":"4"}},{"id":995103,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-11-19T00:02:25.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":false,"shares":1375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1375},"source":{"system":"sec-edgar","filing":"0001655962-25-000006","document":"form4-11192025_121121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000006/form4-11192025_121121.xml","form_type":"4"}},{"id":995102,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2025-11-19T00:02:25.000Z","date":"2025-11-17","kind":"sale","planned":false,"acquired":false,"shares":4062,"price":8.9147,"value":36211.5114,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $8.545 to $9.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":294715,"source":{"system":"sec-edgar","filing":"0001655962-25-000006","document":"form4-11192025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000006/form4-11192025_121121.xml","form_type":"4"}},{"id":995101,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2025-11-19T00:02:25.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":298777,"source":{"system":"sec-edgar","filing":"0001655962-25-000006","document":"form4-11192025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000006/form4-11192025_121121.xml","form_type":"4"}},{"id":995100,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2025-11-19T00:02:25.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":292152,"source":{"system":"sec-edgar","filing":"0001655962-25-000006","document":"form4-11192025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000006/form4-11192025_121121.xml","form_type":"4"}},{"id":995099,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2025-11-19T00:02:25.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":285527,"source":{"system":"sec-edgar","filing":"0001655962-25-000006","document":"form4-11192025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000006/form4-11192025_121121.xml","form_type":"4"}},{"id":995098,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2025-11-19T00:02:25.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":true,"shares":1375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,902 shares of Common Stock acquired by the Reporting Person between May 12, 2023 and November 14, 2025 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":283277,"source":{"system":"sec-edgar","filing":"0001655962-25-000006","document":"form4-11192025_121121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000006/form4-11192025_121121.xml","form_type":"4"}},{"id":1004600,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:03:10.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":162000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":162000,"derivative":{"exercise_price":8.99,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":162000},"source":{"system":"sec-edgar","filing":"0001655962-25-000004","document":"form4-11072025_111106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000004/form4-11072025_111106.xml","form_type":"4"}},{"id":1004599,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:03:10.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":162000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.87,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":162000},"source":{"system":"sec-edgar","filing":"0001655962-25-000004","document":"form4-11072025_111106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000004/form4-11072025_111106.xml","form_type":"4"}},{"id":1004598,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:03:10.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":162000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":162000,"derivative":{"exercise_price":8.99,"expiration_date":"2034-01-04","underlying":"Common Stock","underlying_shares":162000},"source":{"system":"sec-edgar","filing":"0001655962-25-000004","document":"form4-11072025_111106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000004/form4-11072025_111106.xml","form_type":"4"}},{"id":1004597,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:03:10.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":162000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.44,"expiration_date":"2034-01-04","underlying":"Common Stock","underlying_shares":162000},"source":{"system":"sec-edgar","filing":"0001655962-25-000004","document":"form4-11072025_111106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000004/form4-11072025_111106.xml","form_type":"4"}},{"id":1004596,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:03:10.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":116000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":116000,"derivative":{"exercise_price":8.99,"expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":116000},"source":{"system":"sec-edgar","filing":"0001655962-25-000004","document":"form4-11072025_111106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000004/form4-11072025_111106.xml","form_type":"4"}},{"id":1004595,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:03:10.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":116000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":23.41,"expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":116000},"source":{"system":"sec-edgar","filing":"0001655962-25-000004","document":"form4-11072025_111106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000004/form4-11072025_111106.xml","form_type":"4"}},{"id":1004594,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:03:10.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":151000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":151000,"derivative":{"exercise_price":8.99,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":151000},"source":{"system":"sec-edgar","filing":"0001655962-25-000004","document":"form4-11072025_111106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000004/form4-11072025_111106.xml","form_type":"4"}},{"id":1004593,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:03:10.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":151000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.26,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":151000},"source":{"system":"sec-edgar","filing":"0001655962-25-000004","document":"form4-11072025_111106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000004/form4-11072025_111106.xml","form_type":"4"}},{"id":1004592,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:03:10.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":497667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":497667,"derivative":{"exercise_price":8.99,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":497667},"source":{"system":"sec-edgar","filing":"0001655962-25-000004","document":"form4-11072025_111106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000004/form4-11072025_111106.xml","form_type":"4"}},{"id":1004591,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:03:10.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":497667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":497667},"source":{"system":"sec-edgar","filing":"0001655962-25-000004","document":"form4-11072025_111106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000165596225000004/form4-11072025_111106.xml","form_type":"4"}},{"id":1061139,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-08-19T23:40:12.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":86125,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001415889-25-022386","document":"form4-08192025_110809.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925022386/form4-08192025_110809.xml","form_type":"4"}},{"id":1061138,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-08-19T23:40:12.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":59625,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001415889-25-022386","document":"form4-08192025_110809.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925022386/form4-08192025_110809.xml","form_type":"4"}},{"id":1061137,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-08-19T23:40:12.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":11250,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001415889-25-022386","document":"form4-08192025_110809.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925022386/form4-08192025_110809.xml","form_type":"4"}},{"id":1061136,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-08-19T23:40:12.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":false,"shares":1375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":1375,"derivative":{"underlying":"Common Stock","underlying_shares":1375},"source":{"system":"sec-edgar","filing":"0001415889-25-022386","document":"form4-08192025_110809.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925022386/form4-08192025_110809.xml","form_type":"4"}},{"id":1061135,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2025-08-19T23:40:12.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":4106,"price":6.7671,"value":27785.7126,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $6.65 to $6.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":278000,"source":{"system":"sec-edgar","filing":"0001415889-25-022386","document":"form4-08192025_110809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925022386/form4-08192025_110809.xml","form_type":"4"}},{"id":1061134,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2025-08-19T23:40:12.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":282106,"source":{"system":"sec-edgar","filing":"0001415889-25-022386","document":"form4-08192025_110809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925022386/form4-08192025_110809.xml","form_type":"4"}},{"id":1061133,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2025-08-19T23:40:12.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":275481,"source":{"system":"sec-edgar","filing":"0001415889-25-022386","document":"form4-08192025_110809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925022386/form4-08192025_110809.xml","form_type":"4"}},{"id":1061132,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2025-08-19T23:40:12.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":268856,"source":{"system":"sec-edgar","filing":"0001415889-25-022386","document":"form4-08192025_110809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925022386/form4-08192025_110809.xml","form_type":"4"}},{"id":1061131,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2025-08-19T23:40:12.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":true,"shares":1375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":266606,"source":{"system":"sec-edgar","filing":"0001415889-25-022386","document":"form4-08192025_110809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925022386/form4-08192025_110809.xml","form_type":"4"}},{"id":1141810,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-05-19T21:45:58.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":92750,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001415889-25-013679","document":"form4-05192025_090554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925013679/form4-05192025_090554.xml","form_type":"4"}},{"id":1141809,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-05-19T21:45:58.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":66250,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001415889-25-013679","document":"form4-05192025_090554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925013679/form4-05192025_090554.xml","form_type":"4"}},{"id":1141808,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-05-19T21:45:58.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":13500,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001415889-25-013679","document":"form4-05192025_090554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925013679/form4-05192025_090554.xml","form_type":"4"}},{"id":1141807,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-05-19T21:45:58.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":false,"shares":1375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":2750,"derivative":{"underlying":"Common Stock","underlying_shares":1375},"source":{"system":"sec-edgar","filing":"0001415889-25-013679","document":"form4-05192025_090554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925013679/form4-05192025_090554.xml","form_type":"4"}},{"id":1141806,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2025-05-19T21:45:58.000Z","date":"2025-05-16","kind":"sale","planned":false,"acquired":false,"shares":4282,"price":6.2579,"value":26796.3278,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $6.19 to $6.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":265231,"source":{"system":"sec-edgar","filing":"0001415889-25-013679","document":"form4-05192025_090554.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925013679/form4-05192025_090554.xml","form_type":"4"}},{"id":1141805,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2025-05-19T21:45:58.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":269513,"source":{"system":"sec-edgar","filing":"0001415889-25-013679","document":"form4-05192025_090554.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925013679/form4-05192025_090554.xml","form_type":"4"}},{"id":1141804,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2025-05-19T21:45:58.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":262888,"source":{"system":"sec-edgar","filing":"0001415889-25-013679","document":"form4-05192025_090554.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925013679/form4-05192025_090554.xml","form_type":"4"}},{"id":1141803,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2025-05-19T21:45:58.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":256263,"source":{"system":"sec-edgar","filing":"0001415889-25-013679","document":"form4-05192025_090554.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925013679/form4-05192025_090554.xml","form_type":"4"}},{"id":1141802,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2025-05-19T21:45:58.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":true,"shares":1375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":254013,"source":{"system":"sec-edgar","filing":"0001415889-25-013679","document":"form4-05192025_090554.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925013679/form4-05192025_090554.xml","form_type":"4"}},{"id":1252227,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-02-21T23:10:03.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":99375,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001415889-25-005159","document":"form4-02212025_110259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925005159/form4-02212025_110259.xml","form_type":"4"}},{"id":1252226,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-02-21T23:10:03.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":72875,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001415889-25-005159","document":"form4-02212025_110259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925005159/form4-02212025_110259.xml","form_type":"4"}},{"id":1252225,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-02-21T23:10:03.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":15750,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001415889-25-005159","document":"form4-02212025_110259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925005159/form4-02212025_110259.xml","form_type":"4"}},{"id":1252224,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-02-21T23:10:03.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":false,"shares":1375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":4125,"derivative":{"underlying":"Common Stock","underlying_shares":1375},"source":{"system":"sec-edgar","filing":"0001415889-25-005159","document":"form4-02212025_110259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925005159/form4-02212025_110259.xml","form_type":"4"}},{"id":1252223,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2025-02-21T23:10:03.000Z","date":"2025-02-18","kind":"sale","planned":false,"acquired":false,"shares":4370,"price":11.963,"value":52278.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.86 to $12.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":252638,"source":{"system":"sec-edgar","filing":"0001415889-25-005159","document":"form4-02212025_110259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925005159/form4-02212025_110259.xml","form_type":"4"}},{"id":1252222,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2025-02-21T23:10:03.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":257008,"source":{"system":"sec-edgar","filing":"0001415889-25-005159","document":"form4-02212025_110259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925005159/form4-02212025_110259.xml","form_type":"4"}},{"id":1252221,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2025-02-21T23:10:03.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":250383,"source":{"system":"sec-edgar","filing":"0001415889-25-005159","document":"form4-02212025_110259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925005159/form4-02212025_110259.xml","form_type":"4"}},{"id":1252220,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2025-02-21T23:10:03.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":243758,"source":{"system":"sec-edgar","filing":"0001415889-25-005159","document":"form4-02212025_110259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925005159/form4-02212025_110259.xml","form_type":"4"}},{"id":1252219,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2025-02-21T23:10:03.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":true,"shares":1375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":241508,"source":{"system":"sec-edgar","filing":"0001415889-25-005159","document":"form4-02212025_110259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925005159/form4-02212025_110259.xml","form_type":"4"}},{"id":1289130,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Units","published_at":"2025-01-31T21:38:23.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":106000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":106000,"derivative":{"underlying":"Common Stock","underlying_shares":106000},"source":{"system":"sec-edgar","filing":"0001415889-25-002497","document":"form4-01312025_090118.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925002497/form4-01312025_090118.xml","form_type":"4"}},{"id":1289129,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-01-31T21:38:23.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":162000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":162000,"derivative":{"exercise_price":11.87,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":162000},"source":{"system":"sec-edgar","filing":"0001415889-25-002497","document":"form4-01312025_090118.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588925002497/form4-01312025_090118.xml","form_type":"4"}},{"id":1358288,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-11-19T21:30:20.000Z","date":"2024-11-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":79500,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001415889-24-027224","document":"form4-11192024_091114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924027224/form4-11192024_091114.xml","form_type":"4"}},{"id":1358287,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-11-19T21:30:20.000Z","date":"2024-11-15","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":18000,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001415889-24-027224","document":"form4-11192024_091114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924027224/form4-11192024_091114.xml","form_type":"4"}},{"id":1358286,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-11-19T21:30:20.000Z","date":"2024-11-15","kind":"exercise","planned":false,"acquired":false,"shares":1375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":5500,"derivative":{"underlying":"Common Stock","underlying_shares":1375},"source":{"system":"sec-edgar","filing":"0001415889-24-027224","document":"form4-11192024_091114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924027224/form4-11192024_091114.xml","form_type":"4"}},{"id":1358285,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-11-19T21:30:20.000Z","date":"2024-11-18","kind":"sale","planned":false,"acquired":false,"shares":2602,"price":13.2102,"value":34372.9404,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $13.02 to $13.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":240133,"source":{"system":"sec-edgar","filing":"0001415889-24-027224","document":"form4-11192024_091114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924027224/form4-11192024_091114.xml","form_type":"4"}},{"id":1358284,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-11-19T21:30:20.000Z","date":"2024-11-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":242735,"source":{"system":"sec-edgar","filing":"0001415889-24-027224","document":"form4-11192024_091114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924027224/form4-11192024_091114.xml","form_type":"4"}},{"id":1358283,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-11-19T21:30:20.000Z","date":"2024-11-15","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":236110,"source":{"system":"sec-edgar","filing":"0001415889-24-027224","document":"form4-11192024_091114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924027224/form4-11192024_091114.xml","form_type":"4"}},{"id":1358282,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-11-19T21:30:20.000Z","date":"2024-11-15","kind":"exercise","planned":false,"acquired":true,"shares":1375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":233860,"source":{"system":"sec-edgar","filing":"0001415889-24-027224","document":"form4-11192024_091114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924027224/form4-11192024_091114.xml","form_type":"4"}},{"id":1428752,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-08-19T22:07:06.000Z","date":"2024-08-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":86125,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001415889-24-021626","document":"form4-08192024_100802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924021626/form4-08192024_100802.xml","form_type":"4"}},{"id":1428751,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-08-19T22:07:06.000Z","date":"2024-08-15","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":20250,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001415889-24-021626","document":"form4-08192024_100802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924021626/form4-08192024_100802.xml","form_type":"4"}},{"id":1428750,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-08-19T22:07:06.000Z","date":"2024-08-15","kind":"exercise","planned":false,"acquired":false,"shares":1375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6875,"derivative":{"underlying":"Common Stock","underlying_shares":1375},"source":{"system":"sec-edgar","filing":"0001415889-24-021626","document":"form4-08192024_100802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924021626/form4-08192024_100802.xml","form_type":"4"}},{"id":1428749,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-08-19T22:07:06.000Z","date":"2024-08-16","kind":"sale","planned":false,"acquired":false,"shares":2633,"price":13.9991,"value":36859.6303,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."}],"balance_after":232485,"source":{"system":"sec-edgar","filing":"0001415889-24-021626","document":"form4-08192024_100802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924021626/form4-08192024_100802.xml","form_type":"4"}},{"id":1428748,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-08-19T22:07:06.000Z","date":"2024-08-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":235118,"source":{"system":"sec-edgar","filing":"0001415889-24-021626","document":"form4-08192024_100802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924021626/form4-08192024_100802.xml","form_type":"4"}},{"id":1428747,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-08-19T22:07:06.000Z","date":"2024-08-15","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":228493,"source":{"system":"sec-edgar","filing":"0001415889-24-021626","document":"form4-08192024_100802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924021626/form4-08192024_100802.xml","form_type":"4"}},{"id":1428746,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-08-19T22:07:06.000Z","date":"2024-08-15","kind":"exercise","planned":false,"acquired":true,"shares":1375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":226243,"source":{"system":"sec-edgar","filing":"0001415889-24-021626","document":"form4-08192024_100802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924021626/form4-08192024_100802.xml","form_type":"4"}},{"id":1510412,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-05-17T22:15:46.000Z","date":"2024-05-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":92750,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001415889-24-013616","document":"form4-05172024_100532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924013616/form4-05172024_100532.xml","form_type":"4"}},{"id":1510411,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-05-17T22:15:46.000Z","date":"2024-05-15","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":22500,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001415889-24-013616","document":"form4-05172024_100532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924013616/form4-05172024_100532.xml","form_type":"4"}},{"id":1510410,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-05-17T22:15:46.000Z","date":"2024-05-15","kind":"exercise","planned":false,"acquired":false,"shares":1375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":8250,"derivative":{"underlying":"Common Stock","underlying_shares":1375},"source":{"system":"sec-edgar","filing":"0001415889-24-013616","document":"form4-05172024_100532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924013616/form4-05172024_100532.xml","form_type":"4"}},{"id":1510409,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-05-17T22:15:46.000Z","date":"2024-05-16","kind":"sale","planned":false,"acquired":false,"shares":2675,"price":16.0787,"value":43010.5225,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."}],"balance_after":224868,"source":{"system":"sec-edgar","filing":"0001415889-24-013616","document":"form4-05172024_100532.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924013616/form4-05172024_100532.xml","form_type":"4"}},{"id":1510408,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-05-17T22:15:46.000Z","date":"2024-05-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":227543,"source":{"system":"sec-edgar","filing":"0001415889-24-013616","document":"form4-05172024_100532.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924013616/form4-05172024_100532.xml","form_type":"4"}},{"id":1510407,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-05-17T22:15:46.000Z","date":"2024-05-15","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":220918,"source":{"system":"sec-edgar","filing":"0001415889-24-013616","document":"form4-05172024_100532.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924013616/form4-05172024_100532.xml","form_type":"4"}},{"id":1510406,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-05-17T22:15:46.000Z","date":"2024-05-15","kind":"exercise","planned":false,"acquired":true,"shares":1375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":218668,"source":{"system":"sec-edgar","filing":"0001415889-24-013616","document":"form4-05172024_100532.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924013616/form4-05172024_100532.xml","form_type":"4"}},{"id":1527413,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-05-03T22:44:07.000Z","date":"2024-05-03","kind":"sale","planned":true,"acquired":false,"shares":8078,"price":17.8527,"value":144214.1106,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 6, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $17.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":217293,"source":{"system":"sec-edgar","filing":"0001415889-24-012253","document":"form4-05032024_100559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924012253/form4-05032024_100559.xml","form_type":"4"}},{"id":1527412,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-05-03T22:44:07.000Z","date":"2024-05-02","kind":"sale","planned":true,"acquired":false,"shares":200,"price":17.8955,"value":3579.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 6, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.85 to $17.955 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":225371,"source":{"system":"sec-edgar","filing":"0001415889-24-012253","document":"form4-05032024_100559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924012253/form4-05032024_100559.xml","form_type":"4"}},{"id":1527411,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-05-03T22:44:07.000Z","date":"2024-05-01","kind":"sale","planned":true,"acquired":false,"shares":52183,"price":17.887,"value":933397.321,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 6, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $18.04 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":225571,"source":{"system":"sec-edgar","filing":"0001415889-24-012253","document":"form4-05032024_100559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924012253/form4-05032024_100559.xml","form_type":"4"}},{"id":1632580,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-02-20T23:36:11.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":false,"shares":6625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":99375,"derivative":{"underlying":"Common Stock","underlying_shares":6625},"source":{"system":"sec-edgar","filing":"0001415889-24-004469","document":"form4-02202024_110257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924004469/form4-02202024_110257.xml","form_type":"4"}},{"id":1632579,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-02-20T23:36:11.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":24750,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001415889-24-004469","document":"form4-02202024_110257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924004469/form4-02202024_110257.xml","form_type":"4"}},{"id":1632578,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-02-20T23:36:11.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":false,"shares":1375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":9625,"derivative":{"underlying":"Common Stock","underlying_shares":1375},"source":{"system":"sec-edgar","filing":"0001415889-24-004469","document":"form4-02202024_110257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924004469/form4-02202024_110257.xml","form_type":"4"}},{"id":1632577,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-02-20T23:36:11.000Z","date":"2024-02-16","kind":"sale","planned":false,"acquired":false,"shares":2666,"price":15.2481,"value":40651.4346,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."}],"balance_after":277754,"source":{"system":"sec-edgar","filing":"0001415889-24-004469","document":"form4-02202024_110257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924004469/form4-02202024_110257.xml","form_type":"4"}},{"id":1632576,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-02-20T23:36:11.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":true,"shares":6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":280420,"source":{"system":"sec-edgar","filing":"0001415889-24-004469","document":"form4-02202024_110257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924004469/form4-02202024_110257.xml","form_type":"4"}},{"id":1632575,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":51459,"kind":"person","name":"York Charles N II","position":1,"cik":"0001655962","reported_name":"York Charles N II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO AND SECRETARY"}}],"security":"Common Stock","published_at":"2024-02-20T23:36:11.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":273795,"source":{"system":"sec-edgar","filing":"0001415889-24-004469","document":"form4-02202024_110257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655962/000141588924004469/form4-02202024_110257.xml","form_type":"4"}}],"next_cursor":"2024-02-20T23:36:11.000000Z,1632575"}